EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Klinische Studie (Phase I)Open Access · CC BY-NC-ND 4.0

Population Pharmacokinetic and Pharmacodynamic Modeling for the Prediction of the Extended Amlitelimab Phase 3 Dosing Regimen in Atopic Dermatitis

Gilles Tiraboschi, Kim Papp iD, Thomas Bieber iD, Stephan Weidinger iD, Lisa Beck iD, Chih-Hung Lee iD, John T O'Malley iD, Karl Yen iD, Charlotte Bernigaud iD, David Fabre, Fabrice Hurbin

CPT: Pharmacometrics & Systems Pharmacology · 2025

DOI: 10.1002/psp4.70121 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2025. Verfasst von Gilles Tiraboschi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Sanofi, Montpellier, France. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Antibodies, Monoclonal, Humanized, Models, Biological. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Amlitelimab is a fully human, nondepleting, anti‐OX40 ligand monoclonal antibody being investigated for the treatment of moderate‐to‐severe atopic dermatitis (AD) in adults and adolescents. Population pharmacokinetic (PopPK) and pharmacokinetic/pharmacodynamic‐Eczema Area and Severity Index (PopPK/PD‐EASI) models were used to inform dosing regimen selection for amlitelimab phase 3 trials. The PopPK model was developed using phase 1 (healthy volunteers) and phase 2 (participants with AD) trial data, including individual exposure variables from the STREAM‐AD phase 2b trial following subcutaneous amlitelimab doses ranging from 62.5 to 250 mg given every 4 weeks (Q4W). The PopPK model was used to compute exposures for an extended dosing regimen of 250 mg Q12W (with 500 mg loading dose [+LD]). The PopPK/PD‐EASI model was developed from phase 2 trials to predict treatment responses (EASI values) with selected dosing scenarios. Finally, the dose for individuals with lower body weight (i.e., < 40 kg) was determined. Utilizing the PopPK model, the amlitelimab 250 mg Q12W + LD computed exposures were between the exposures of 62.5 mg Q4W and 250 mg Q4W + LD efficacious doses in the STREAM‐AD trial. Using the PopPK/PD‐EASI model, the simulated efficacy for dosing scenarios of 250 mg Q12W + LD regimen from initiation or 250 mg Q4W + LD for 24 weeks followed by Q12W to Week 60 was similar to continuous 250 mg Q4W. Simulations identified that a twofold dose reduction would allow participants < 40 kg to achieve amlitelimab exposures within the range observed in participants ≥ 40 kg on 250 mg Q4W or Q12W. These results support evaluation of a Q12W dosing regimen for adults and adolescents in phase 3 trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicAntibodies, Monoclonal, HumanizedModels, BiologicalHumansAdultMaleFemaleAdolescentDose-Response Relationship, DrugMiddle AgedYoung AdultSeverity of Illness IndexDrug Administration Schedule

Stichwörter der Autor:innen

clinical trialsinflammationmodelingpopulation pharmacokineticspopulation pharmacokinetics‐pharmacodynamics

Substanzen

Antibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Sanofi, Montpellier, France.
  • Alliance Clinical Trials and Probity Medical Research, Waterloo, Ontario, Canada.
  • Division of Dermatology, Temerty School of Medicine, University of Toronto, Toronto, Ontario, Canada.
  • Christine Kühne-Center for Allergy Research and Education, Medicine Campus, Davos, Switzerland.
  • Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Kiel, Germany.
  • Department of Dermatology, University of Rochester Medical Center, Rochester, New York, USA.

ORCID-Profile: Kim Papp, Thomas Bieber, Stephan Weidinger, Lisa Beck, Chih-Hung Lee, John T O'Malley, Karl Yen, Charlotte Bernigaud

Zitieren

APA

Tiraboschi, G., Papp, K., Bieber, T., Weidinger, S., Beck, L., Lee, C. H., O'Malley, J. T., Yen, K., Bernigaud, C., Fabre, D., & Hurbin, F. (2025). Population Pharmacokinetic and Pharmacodynamic Modeling for the Prediction of the Extended Amlitelimab Phase 3 Dosing Regimen in Atopic Dermatitis. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.70121

Vancouver

Tiraboschi G, Papp K, Bieber T, Weidinger S, Beck L, Lee CH, et al. Population Pharmacokinetic and Pharmacodynamic Modeling for the Prediction of the Extended Amlitelimab Phase 3 Dosing Regimen in Atopic Dermatitis. CPT: Pharmacometrics & Systems Pharmacology. 2025. doi:10.1002/psp4.70121

BibTeX
@article{Tiraboschi2025,
  author = {Tiraboschi, Gilles and Papp, Kim and Bieber, Thomas and Weidinger, Stephan and Beck, Lisa and Lee, Chih-Hung and O'Malley, John T and Yen, Karl and Bernigaud, Charlotte and Fabre, David and Hurbin, Fabrice},
  title = {Population Pharmacokinetic and Pharmacodynamic Modeling for the Prediction of the Extended Amlitelimab Phase 3 Dosing Regimen in Atopic Dermatitis},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2025},
  doi = {10.1002/psp4.70121}
}
Kostenlos starten →